AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 81 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,537,965 | +55.3% | 3,413,906 | 0.0% | 0.04% | +54.2% |
| Q1 2023 | $990,033 | -35.5% | 3,413,906 | 0.0% | 0.02% | -35.1% |
| Q4 2022 | $1,535,916 | -14.5% | 3,413,906 | 0.0% | 0.04% | -19.6% |
| Q3 2022 | $1,796,000 | +15.7% | 3,413,906 | +11.1% | 0.05% | +2.2% |
| Q2 2022 | $1,552,000 | -62.7% | 3,072,034 | +69.6% | 0.04% | -57.1% |
| Q1 2022 | $4,166,000 | -44.4% | 1,811,425 | +14.8% | 0.10% | -39.3% |
| Q4 2021 | $7,492,000 | -40.3% | 1,577,296 | 0.0% | 0.17% | -34.5% |
| Q3 2021 | $12,540,000 | +14.2% | 1,577,296 | 0.0% | 0.26% | +21.7% |
| Q2 2021 | $10,978,000 | -12.1% | 1,577,296 | 0.0% | 0.22% | -20.5% |
| Q1 2021 | $12,492,000 | +0.5% | 1,577,296 | -0.2% | 0.27% | +3.4% |
| Q4 2020 | $12,435,000 | +10.3% | 1,580,000 | -0.7% | 0.26% | -7.7% |
| Q3 2020 | $11,277,000 | -23.3% | 1,590,528 | 0.0% | 0.29% | -29.2% |
| Q2 2020 | $14,712,000 | +294.6% | 1,590,528 | +98.8% | 0.40% | +162.3% |
| Q1 2020 | $3,728,000 | -39.0% | 800,000 | 0.0% | 0.15% | -20.2% |
| Q4 2019 | $6,112,000 | -0.7% | 800,000 | 0.0% | 0.19% | -21.2% |
| Q3 2019 | $6,152,000 | +12.3% | 800,000 | 0.0% | 0.24% | +23.7% |
| Q2 2019 | $5,480,000 | -14.9% | 800,000 | 0.0% | 0.20% | -20.2% |
| Q1 2019 | $6,440,000 | +32.3% | 800,000 | +23.1% | 0.25% | +7.8% |
| Q4 2018 | $4,869,000 | -21.7% | 650,000 | 0.0% | 0.23% | +2.2% |
| Q3 2018 | $6,221,000 | -9.5% | 650,000 | 0.0% | 0.22% | -15.1% |
| Q2 2018 | $6,877,000 | +32.3% | 650,000 | +24.0% | 0.26% | +19.4% |
| Q1 2018 | $5,199,000 | +83.4% | 524,089 | 0.0% | 0.22% | +72.1% |
| Q4 2017 | $2,835,000 | +9.7% | 524,089 | 0.0% | 0.13% | +8.4% |
| Q3 2017 | $2,584,000 | +28.4% | 524,089 | 0.0% | 0.12% | +16.7% |
| Q2 2017 | $2,013,000 | -48.4% | 524,089 | 0.0% | 0.10% | -54.7% |
| Q1 2017 | $3,904,000 | +71.2% | 524,089 | 0.0% | 0.22% | +47.1% |
| Q4 2016 | $2,280,000 | -32.1% | 524,089 | 0.0% | 0.15% | -27.5% |
| Q3 2016 | $3,359,000 | +31.9% | 524,089 | 0.0% | 0.21% | +11.6% |
| Q2 2016 | $2,547,000 | – | 524,089 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $532,000 | 6.17% |
| Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
| GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
| Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
| Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
| Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
| Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
| Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |